Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India · Delayed Price · Currency is INR 883.75
-16.95 (-1.88%)
At close: Jan 14, 2026
Zydus Lifesciences Employees
Zydus Lifesciences had 27,917 employees as of March 31, 2025. The number of employees increased by 996 or 3.70% compared to the previous year.
Employees
27,917
Change (1Y)
996
Growth (1Y)
3.70%
Revenue / Employee
8.77M INR
Profits / Employee
1.76M INR
Market Cap
889.26B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 27,917 | 996 | 3.70% |
| Mar 31, 2024 | 26,921 | 3,895 | 16.92% |
| Mar 31, 2023 | 23,026 | -717 | -3.02% |
| Mar 31, 2022 | 23,743 | -669 | -2.74% |
| Mar 31, 2021 | 24,412 | -588 | -2.35% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sun Pharmaceutical Industries | 43,000 |
| Apollo Hospitals Enterprise | 42,497 |
| Cipla | 30,313 |
| Aurobindo Pharma | 27,707 |
| Mankind Pharma | 26,978 |
| Alkem Laboratories | 18,785 |
| Biocon | 16,315 |
| Glenmark Pharmaceuticals | 15,800 |
Zydus Lifesciences News
- 1 day ago - Zydus Lifesciences’ US arm Sentynl secures FDA approval for ZYCUBO, first-ever treatment for Menkes disease - Business Upturn
- 2 days ago - Delhi HC clears Zydus biosimilar, boosting access to affordable cancer care - The Times of India
- 22 days ago - Zydus Lifesciences, Bioeq Sign Agreement To Commercialize NUFYMCO In US - Nasdaq
- 22 days ago - Zydus Lifesciences shares in focus today after High Court allows semaglutide manufacturing for exports - Business Upturn
- 26 days ago - Zydus Lifesciences signs exclusive agreement with Myriad Genetics to launch advanced cancer genomic tests in India - Business Upturn
- 4 weeks ago - Top stocks to watch today, December 16: HCL Technologies, TCS, RBL Bank, Delhivery, Zydus Lifesciences and more - Business Upturn
- 5 weeks ago - Zydus Lifesciences launches ‘Zyrifa’, a Denosumab biosimilar for advanced cancer-related bone complications - Business Upturn
- 5 weeks ago - Zydus Lifesciences receives EIR from USFDA for the injectable facility at Jarod - Business Upturn